Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
LGND
LGND
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGND News
Ligand Pharmaceuticals Q1 Earnings Announcement Scheduled
4d ago
seekingalpha
Investigation Alerts for Multiple Company Mergers
5d ago
Globenewswire
Latest Developments in the Biotech Sector
Apr 30 2026
NASDAQ.COM
Investigation into XOMA Royalty Acquisition
Apr 27 2026
PRnewswire
Investigation Alerts for Multiple Mergers
Apr 27 2026
Globenewswire
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
Apr 27 2026
NASDAQ.COM
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
Apr 27 2026
seekingalpha
Ligand Pharmaceuticals to Acquire XOMA for $740M in Cash
Apr 27 2026
seekingalpha
XOMA STOCK RISES 5.4% IN PREMARKET TRADING FOLLOWING REPORT OF LIGAND PHARMACEUTICALS ACQUIRING COMPANY FOR ALMOST $740 MILLION
Apr 27 2026
moomoo
LIGAND PHARMACEUTICALS' AGREEMENT WITH XOMA WOULD ESTABLISH XOMA'S VALUE AT $39 PER SHARE - WSJ
Apr 27 2026
moomoo
Ligand Pharmaceuticals Acquires Xoma for Approximately $740 Million - WSJ
Apr 27 2026
moomoo
FDA Approves Filspari for Rare Kidney Disorder Treatment
Apr 14 2026
stocktwits
FDA Approves Travere and Ligand's Joint Kidney Disease Therapy Expansion
Apr 14 2026
seekingalpha
Ligand's Partner Receives FDA Approval for FSGS Treatment
Apr 14 2026
NASDAQ.COM
FILSPARI Receives FDA Approval for FSGS Treatment
Apr 14 2026
Newsfilter
Travere Therapeutics Receives FDA Approval for New Drug
Apr 14 2026
stocktwits
Show More News
